Clinical Trials Browser

Glioma

NCT02016872 2025-04-30

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Phase NA Completed

25 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03649880 2025-03-25

Feasibility of FMISO in Brain Tumors

Phase 2 Recruiting

50 enrolled

CNS

Brain Neoplasms

NCT05250895 2025-03-13

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

Phase EARLY_PHASE1 Completed

9 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06087614 2025-01-17

DE-HyART

Phase 2 Recruiting

124 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01246869 2024-10-01

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

Phase 1 Terminated

2 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Neoplasms

NCT05996432 2024-09-23

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Phase EARLY_PHASE1 Recruiting

48 enrolled

CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Brain Neoplasms

NCT00606294 2023-06-28

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

Phase NA Completed

216 enrolled 9 charts

Head & Neck

Head and Neck Neoplasms

NCT03730077 2021-03-18

FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas

Phase 1 Terminated

5 enrolled

Sarcoma

NCT03303469 2021-02-21

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Phase 2 Terminated

3 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03573986 2020-02-17

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Phase 1 Terminated

2 enrolled

CNS

Glioblastoma

NCT01868906 2018-08-24

FMISOPETSCS

Phase 2 Terminated

6 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Skin Neoplasms

NCT00038038 2012-08-01

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Phase NA Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis

Clinical Trials

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Feasibility of FMISO in Brain Tumors

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

DE-HyART

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

FMISOPETSCS

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole